HAYA Therapeutics SA
Epalinges
The company HAYA Therapeutics SA currently has 3 open positions.
Epalinges
The company HAYA Therapeutics SA currently has 3 open positions.
Haya Therapeutics SA , Epalinges
1+m
Haya Therapeutics SA , Epalinges
1+m
Haya Therapeutics SA , Epalinges
1+m
Conditions of Employment: Proof of Eligibility to work in Switzerland (Swiss work permit or Swiss / European citizenship)
So, if you think you are a strong fit for this position, please apply today!
Please send your CV and Cover Letter to Write an email. Please specify the position you are applying for.
Excellent salary and benefits package offered.
About the job
We are seeking highly motivated candidates to join our R&D team in Lausanne and contribute to the development and application of advanced technologies in RNA-based therapeutics and diagnostics.
HAYA seeks candidates who are creative, scientifically bold, independent, goal-oriented, excellent communicators, motivated to learn new skills and work collaboratively in a fast-paced entrepreneurial environment.
Senior Genomic Biomarker Scientist
As an experienced and engaged Senior Genomic Biomarker Scientist, you will work in close collaboration with computational biology and pre-clinical R&D teams. You will apply your scientific acumen and creativity to build ViewHAYATM, a top-notch platform for biomarker discovery and validation. You will drive this platform forward to identify and develop CDx for HAYA’s therapeutic assets. You will provide matrix leadership and inspire others with your creative ideas as well as your technological and domain insights.
Responsibilities will include, but are not limited to, the following:
Qualifications:
Core Values:
HAYA Therapeutics is a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer. The company is using its innovative cell-state modifying platform to gain novel insights into the biology of long non-coding RNAs (lncRNAs), - the ‘dark genomes’ information processing features and ‘source code’.
HAYA’s lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting Wisper, which is a tissue and cell-specific cardiac lncRNA known to play a role in heart failure. The company is also developing a pipeline of lncRNA-targeting candidates for the cell-specific treatment of diseases in other tissues, including the lungs and the microenvironment of solid tumor cancers.
Headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at JLABS @ San Diego, HAYA is led by a world-class team of experts in programmable and precision RNA-targeted therapeutics and is supported by a strong investor consortium. HAYA’s mission is to identify and develop breakthrough disease-modifying therapeutics with the potential for greater efficacy, safety, and accessibility than existing treatments.